• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fresh2 Group Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    4/2/24 4:23:50 PM ET
    $FRES
    Medical Specialities
    Health Care
    Get the next $FRES alert in real time by email
    false 0001786511 00-0000000 0001786511 2024-03-27 2024-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 27, 2024

     

    Fresh2 Group Limited
    (Exact name of Company as specified in its charter)

     

    British Virgin Islands   001-39137   Not Applicable
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    650 5TH AVE STE 2416

    NEW YORK,

    United States

      NY 10019-6108
    (Address of principal executive offices)   (Zip Code)

     

    Company’s telephone number, including area code: 917-397-6890

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    American depositary shares (each representing 20 Class A ordinary shares, par value US$0.01 per share)   FRES   Nasdaq Capital Market

     

    Indicate by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    As previously reported, on September 22, 2023, Fresh2 Group Limited (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor (the “Investor”) to purchase (i) $400,000 of its convertible notes and warrants to purchase its American Depositary Shares (“ADSs”) in a registered direct offering (the “First Tranche”) and (ii) an additional $1,600,000 of its convertible notes and warrants to purchase its ADSs in a follow-on registered direct offering. The First Tranche closed on September 25, 2023.

     

    Due to certain delays, the Company and the Investor entered into an amendment to the Securities Purchase Agreement, under which the parties agreed to reduce the second tranche to (i) $500,000 of convertible notes, (ii) series C warrants to purchase up to 322,581 ADSs, and (iii) series D warrants to purchase up to 354,610 ADSs (the “Second Tranche”). The parties also agreed that the closing(s) of the remaining amount of the convertible notes, series C warrants, and series D warrants would occur on the date(s) to be mutually agreed upon by us and the Investor in the future. The Second Tranche closed on December 6, 2023.

     

    On March 27, 2024, the Company issued $200,000 of its convertible notes (the “Convertible Note”) to the Investor. On the same date, the Company issued a warrant letter to the Investor, which clarifies that the aggregate exercise price for the ordinary shares of the Company upon the exercise of the warrants issued by the Company in the First Tranche and the Second Tranche shall be calculated as the quotient obtained by dividing (x) the aggregate exercise price of ADSs for such exercise, by (y) twenty (20).

     

    The foregoing description of the Convertible Note and the Warrant Letter does not purport to be complete and is qualified in its entirety by reference to the documents, the form of which are filed as Exhibit 10.1 and 10.2 hereto and are incorporated herein by reference.

      

    Item 2.03 Creation of a Direct Financial Obligation

     

    The disclosure set forth in Item 1.01 above is incorporated herein by reference.

     

    Item 3.02. Unregistered sales of equity securities.

     

    The disclosure set forth in Item 1.01 above is incorporated herein by reference.

     

    Item 9.01. Financial Statement and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No   Document
    10.1   Convertible Note, dated March 27, 2024
    10.2   Warrant Letter, dated March 27, 2024
    104   Cover Page Interactive Data File, formatted in Inline XBRL

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: April 2, 2024 Fresh2 Group Limited
       
      By: /s/ Haohan Xu
      Name:  Haohan Xu
      Title: Chief Executive Officer

     

     

    2

     

    Get the next $FRES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresh2 Group Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

    New York, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or the "Company"), a  B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on October 16, 2024, it received a Staff Determination Letter from the Nasdaq Stock Market LLC ("Nasdaq")  indicating that the Company did not comply with Nasdaq's filing requirements as set forth in Listing Rule 5250(c)(1). The letter is a result of the Company's failure to file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, and June 30, 2024, within the required deadlines. Nasdaq had previously granted

    10/17/24 4:05:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Group Ltd. Announces Receipt of an Additional Delinquency Compliance Alert Notice from Nasdaq

    New York, NY, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or the "Company"), a  B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on August 19 , 2024, it received an additional delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising they have not received the Company's Form 10-Q for the period ended June 30, 2024, it does not comply with the Listing Rules 5250(c)(1) (the "Rules"), which requires the timely filing of all required periodic reports with the SEC. Previously, Nasdaq Staff had granted the Company an exception

    8/22/24 4:05:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Announces Collaboration with Over 50 Influencers in Video E-commerce

    New York, NY, July 16, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that its video e-commerce business has partnered with over 50 influencers, resulting in continued rapid sales growth. By leveraging these key partnerships, Fresh2's video e-commerce business is rapidly expanding its market presence in the e-commerce sector. (Screenshot of some Company's venues at tiktok) The Power of Video E-commerce Unlike traditional e-commerce, video e-commerce uses multimedia formats, which offer stronger visual appeal and can hi

    7/16/24 9:15:00 AM ET
    $FRES
    Medical Specialities
    Health Care

    $FRES
    SEC Filings

    View All

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    12/23/24 4:02:53 PM ET
    $FRES
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    11/14/24 4:15:32 PM ET
    $FRES
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    7/24/24 4:01:19 PM ET
    $FRES
    Medical Specialities
    Health Care

    $FRES
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of New Independent Director

    NEW YORK, Dec. 15, 2023 /PRNewswire/ -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced the appointment of Zhijun (Michael) Liang, as an independent director of the Company, effective January 1, 2024. Zhijun (Michael) Liang, has spent more than two decades providing management consulting and investment management services, primarily to start-ups and growth businesses, enabling them to address expansion needs and financial challenges. He co-founded Beijing Yuantong Funds Management Co., Ltd., and has led its risk and investment management since 2018. Concurrently, as the

    12/15/23 4:01:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Group Ltd. Appoints New Chief Strategy Officer to Drive Advancement and Execution of Long-Term Growth Strategy

    NEW YORK, July 26, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ:FRES) ("Fresh2," the "Company" or "we"), a company with operations in the United States and China focused on the business-to-business e-commerce and supply chain sectors for the restaurant supply and food industry and on early cancer screening and detection,  today announced the appointment of Mr. Yidong Hu as its Chief Strategy Officer (CSO) effective on July 21, 2023. Mr. Hu was appointed to drive the advancement and execution of the Company's long-term strategy. Mr. Hu is a seasoned executive with over a decade of experience in the media and finance sectors. Mr.Hu has served as

    7/26/23 9:00:00 AM ET
    $FRES
    Medical Specialities
    Health Care